Board of Directors November Meeting Highlights
Board of Directors November Meeting Highlights
Not: pictured: Jordan S. Orange, MD, PhD, FAAAAI; Allison Ramsey, MD, FAAAAI
The members of the AAAAI Board of Directors met November 21-23, 2025, in Washington, DC, to discuss current and future activities. Board members also heard presentations from representatives from Hart Health Strategies, Inc., the FDA Center for Biologics Evaluation and Research (CBER), the FDA Center for Drug Evaluation and Research (CDER), the National Institute of Health (NIH)/National Institute of Allergy & Infectious Diseases (NIAID), and the National Heart, Lung and Blood Institute (NHLBI).
The members of the Board of Directors appreciate the hard work of all of the AAAAI committee members and Chairs as they strive toward the AAAAI mission to advance the knowledge and practice of allergy, asthma and immunology for optimal patient care, while also operating within our current Strategic Plan. Over the course of the meeting, several significant decisions were made. Here are the highlights:
Approvals
A number of requests were granted approval, including the 2026 AAAAI and AAAAI Foundation operating budgets, continued funding for the Joint Task Force on Practice Parameters and the Joint Board Review Course. The Board also approved funding for new software programs; one for state legislation tracking and member engagement for federal and state advocacy campaigns and one to centralize AAAAI’s online recorded content and other educational resources.
Presidential Presentations
Frank S. Virant, MD, FAAAAI, provided additional information on his presidential initiatives, including updates for the upcoming Practice Management Course at the 2026 AAAAI Annual Meeting and his continued work on the creation of a digital publication and PDF version of “The Value of Allergy & Immunology Specialists: Partners in Optimizing Patient Care,” for which funding was also approved.
Carla M. Davis, MD, FAAAAI, provided an update on her coming presidential initiatives, centered on advancing access to the allergy/immunology specialty, including:
- Leveraging technology and AI to personalize opportunities within the AAAAI
- Supporting, evaluating and strengthening research initiatives
- Influencing policy makers at the congressional, regulatory and state levels to emphasize that patient voices are critical.
Miscellaneous
The Board selected Marcus S. Shaker, MD, MS, FAAAAI, to serve as the 2026 At-Large Executive Committee member, beginning at the close of the 2026 AAAAI Annual Meeting.
In addition, the three divisions of the Board of Directors—Education, Practice & Policy and Research & Training—met individually to discuss committee activities.
A number of other projects and topics were discussed and approved including enhancements to the AAAAI website for accessibility and an updated AAAAI Learner’s Bill of Rights, which will continue to ensure that the educational programming AAAAI provides is clinically valid, reliable and accurate, and done in an environment that supports learners’ ability to meet their individual needs.
What
The next Board of Directors meeting
When
February 25-26, 2026
Where
Philadelphia, PA